David Larsen, MD
Family Medicine · Salt Lake City, UTNPI 1679548564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 472 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$770
- Lilly USA, LLC$586
- Pfizer$569
- Boehringer Ingelheim$464
- Johnson & Johnson$442
- Amgen$436
- plus $4K from 50 others
Across 332 payments — averaging $3954.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$647K
- Biohaven Pharmaceutical Holding Company Ltd.$280K
- American Regent$170K
- H. Lundbeck A S$113K
- GRT US Holding, Inc.$76K
- Biohaven Pharmaceuticals, Inc.$26K
- plus $2K from 1 others
What the payments were for
- Food & beverage$7,556100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,580 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 26 | $51,933 |
| EliquisApixaban | 48 | $51,101 |
| XareltoRivaroxaban | 27 | $41,163 |
| MounjaroTirzepatide | 32 | $41,084 |
| OzempicSemaglutide | 18 | $27,556 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,008 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,540 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $7,319 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,070 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 227 | $4,636 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,584 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 114 | $4,031 |
| Levothyroxine Sodium | 366 | $3,910 |
| Omeprazole | 221 | $3,750 |
| Oxycodone Hcl | 167 | $3,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $586 | $93,01658 claims |
| PfizerEliquis | $569 | $51,10148 claims |
| Johnson & JohnsonXarelto | $442 | $41,16327 claims |
| Novo NordiskOzempic | $412 | $27,55618 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $304 | $17,61028 claims |
| AstraZenecaBevespi Aerosphere | $377 | $4,58411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Mark CacciamaniSalt Lake City$43K
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.